Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
A multicentre two-part phase I/II study evaluating response and safety of SORAFENIB in
combination with irinotecan in the second line treatment or more of metastatic colorectal
cancer with K-RAS mutation.